A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
University of Nebraska
Daiichi Sankyo
Mayo Clinic
Seagen Inc.
Hoffmann-La Roche
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
City of Hope Medical Center
Alliance Foundation Trials, LLC.
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Hoffmann-La Roche
Dana-Farber Cancer Institute
University of Chicago
Pfizer
Fundacio Clinic Barcelona
National Cancer Institute (NCI)
University of California, San Francisco
Seagen Inc.
Merck Sharp & Dohme LLC
Hoffmann-La Roche
University of Nebraska
Dana-Farber Cancer Institute
City of Hope Medical Center
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
City of Hope Medical Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Texas Southwestern Medical Center
University of California, San Francisco
Menarini Group
National Cancer Institute (NCI)
City of Hope Medical Center
MacroGenics
City of Hope Medical Center
M.D. Anderson Cancer Center
Astellas Pharma Inc
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Novartis
Novartis
MacroGenics